About Penta
Who we are
Diversity and Inclusion
Our Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Brighter Future Award
Archivio
PENTA guidelines for the use of antiretroviral therapy 2004
72-week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance outcomes in the PENTA 7 study
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens